Biomerica, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Zackary S. Irani
- Full Time Employees
- 64
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 17571 Von Karman Avenue Irvine CA United States of America 92614
- IPO Date
- Sep 7, 1984
- CIK
- 0000073290
- Website
- biomerica.com
- Similar Companies
- Business
- Biomerica, Inc. (Nasdaq: BMRA) develops, manufactures, and markets advanced diagnostic and therapeutic products worldwide, with a primary focus on gastrointestinal diseases, food intolerances, inflammatory conditions, diabetes, and esoteric testing. The company offers diagnostic test kits that analyze blood, urine, nasal, or fecal specimens to detect diseases, medical complications, bacteria, hormones, antibodies, antigens, and other substances; key products include InFoods IBS, a blood-based test identifying patient-specific foods to alleviate irritable bowel syndrome symptoms; hp+detect for H. Pylori infection; tests for anemia, bone and mineral metabolism, colorectal disease and fecal occult blood, endocrinology, kidney disease, men's health, women's health, and colorectal cancer screening; point-of-care and at-home self-testing solutions; ELISA and multiplex ELISA assays; and contract development and manufacturing organization (CDMO) services encompassing assay development, antibody conjugation, recombinant antibody production, and scalable manufacturing in lateral flow, point-of-care diagnostics, and automated assembly. Biomerica operates through clinical labs, physicians' offices, over-the-counter drugstores, hospital laboratories, and direct-to-consumer channels, serving customers in Asia (primary revenue source), Europe, North America, the Middle East, South America, and other regions; it maintains manufacturing facilities in Irvine, California, and Mexicali, Mexico, both ISO 13485-certified and FDA-registered. Founded in 1971 and headquartered in Irvine, California, the company has expanded its footprint with recent strategic developments, including a October 2025 marketing services agreement with Henry Schein, Inc. to promote InFoods IBS nationwide (excluding New York); expansion of CDMO services in November 2025 to address demand for custom diagnostics from biotech firms; an exclusive distribution agreement in the United Arab Emirates for at-home cancer screening products; initiation of a pilot program for InFoods IBS; U.S. office expansions; and five new patents for InFoods technology in Europe, Canada, and Japan.
Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development
Biomerica's inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026
Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway
Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs
Biomerica Reports Third Quarter Fiscal 2026 Financial Results
Biomerica (BMRA) to Post Earnings on Monday
Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe
Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain
Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy
Biomerica (NASDAQ:BMRA) Stock Passes Below 200 Day Moving Average – Here’s Why
Vietnam Approves Biomerica's EZ Detect™ for Nationwide Distribution
Biomerica Reports Second Quarter Fiscal 2026 Financial Results
Short Interest in Biomerica, Inc. (NASDAQ:BMRA) Expands By 123.2%
Biomerica (NASDAQ:BMRA) Share Price Crosses Below Two Hundred Day Moving Average – Time to Sell?
Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test
Biomerica (NASDAQ:BMRA) Stock Crosses Below 200-Day Moving Average – What’s Next?
Egyptian Drug Authority Authorizes Biomerica's Complete Screening Test Portfolio
Biomerica's inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS
Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand
Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica's inFoods® IBS Test in the U.S.